Pivotal Study ISO-CC-007

Successful End-of-Phase 2
meeting with FDA and
Phase 3 Program for
arfolitixorin (Modufolin®) agreed

Read More

Candidate

arfolitixorin (Modufolin®)
A BETTER AND MORE EFFICIENT TREATMENT

Read more

Common treatment

Folates are the most

commonly used drugs in cancer

treatment today

Read more

Situation of today

A majority of patients do not
fully benefit from their
folate treatment today

Read more

About arfolitixorin (Modufolin®)

arfolitixorin (Modufolin®) holds the
potential to replace all
folates in cancer treatments

Read more

Devlopment Status

US and EU regulatory
authorities have endorsed the
arfolitixorin (Modufolin®) development plan

Read more

Previous

Next

Startpage 2